Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma

References

• Chua ML, Wee JT, Hui EP, Chan AT. Nasopharyngeal carcinoma. Lancet 2016; 387:1012-24; PMID:26321262; https://doi.org/10.1016/S0140-6736(15)00055-0
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86; PMID:25220842; https://doi.org/10.1002/ijc.29210
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China. 2015. CA Cancer J Clin 2016; 66:115-32; PMID:26808342; https://doi.org/10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Xu C, Chen YP, Ma J. Clinical trials in nasopharyngeal carcinoma-past, present and future. Chin Clin Oncol 2016; 5:20; PMID:27121880; https://doi.org/10.21037/cco.2016.03.12
   PubMed Web of Science ®Google Scholar
• Vogler M. Targeting BCL2-Proteins for the treatment of solid tumours. Adv Med 2014; 2014:943648; PMID:26556430; https://doi.org/10.1155/2014/943648
   PubMedGoogle Scholar
• Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, Nikolovska-Coleska Z, Wang S, Al-Katib A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007; 13:2226-35; PMID:17404107; https://doi.org/10.1158/1078-0432.CCR-06-1574
   PubMed Web of Science ®Google Scholar
• Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC, Nikolovska-Coleska Z, Bengtson A, Nair R, Elder JT, et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66:11348-59; PMID:17145881; https://doi.org/10.1158/0008-5472.CAN-06-1748
   PubMed Web of Science ®Google Scholar
• Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, Sarkar FH, Mohammad RM. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: Involvement of Notch-1 signaling pathway. Cancer Res 2009; 69:2757-65; PMID:19318573; https://doi.org/10.1158/0008-5472.CAN-08-3060
   PubMed Web of Science ®Google Scholar
• Ouchi K, Kuwahara Y, Iehara T, Miyachi M, Katsumi Y, Tsuchiya K, Konishi E, Yanagisawa A, Hosoi H. A NOXA/MCL-1 imbalance underlies chemoresistance of malignant rhabdoid tumor cells. J Cell Physiol 2016; 231:1932-40; PMID:26680268; https://doi.org/10.1002/jcp.25293
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Z, Wei X, Dai R. Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. J Ovarian Res 2015; 8:3; PMID:25823945; https://doi.org/10.1186/s13048-015-0130-x
   PubMed Web of Science ®Google Scholar
• Lin X, Liu S, Luo X, Ma X, Guo L, Li L, Li Z, Tao Y, Cao Y. EBV-encoded LMP1 regulates Op18/stathmin signaling pathway by cdc2 mediation in nasopharyngeal carcinoma cells. Int J Cancer 2009; 124:1020-7; PMID:19048596; https://doi.org/10.1002/ijc.23767
   PubMed Web of Science ®Google Scholar
• Du CW, Wen BG, Li DR, Lin YC, Zheng YW, Chen L, Chen JY, Lin W, Wu MY. Latent membrane protein-1 of Epstein - Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell. Exp Oncol 2005; 27:267-72; PMID:16404345
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 2013; 20:1475-84; PMID:23832116; https://doi.org/10.1038/cdd.2013.79
   PubMed Web of Science ®Google Scholar
• Brumatti G, Ekert PG. Seeking a MCL-1 inhibitor. Cell Death Differ 2013; 20:1440-1; PMID:24096932; https://doi.org/10.1038/cdd.2013.114
   PubMed Web of Science ®Google Scholar
• Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61:1107-16; PMID:15752890; https://doi.org/10.1016/j.ijrobp.2004.07.702
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17:1509-20; PMID:27686945; https://doi.org/10.1016/S1470-2045(16)30410-7
   PubMed Web of Science ®Google Scholar
• Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68:2321-8; PMID:18381439; https://doi.org/10.1158/0008-5472.CAN-07-5031
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 2016; 538:477-82; PMID:27760111; https://doi.org/10.1038/nature19830
   PubMed Web of Science ®Google Scholar
• Renault TT, Elkholi R, Bharti A, Chipuk JE. B cell lymphoma-2 (BCL-2) homology domain 3 (BH3) mimetics demonstrate differential activities dependent upon the functional repertoire of pro- and anti-apoptotic BCL-2 family proteins. J Biol Chem 2014; 289:26481-91; PMID:25096574; https://doi.org/10.1074/jbc.M114.569632
   PubMed Web of Science ®Google Scholar
• Vela L, Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: The long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol 2015; 23:74-81; PMID:26079328; https://doi.org/10.1016/j.coph.2015.05.014
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 2011; 74:481-5; PMID:21620511; https://doi.org/10.1016/j.lungcan.2011.05.005
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, Murphy SC, Erlichman C, Rudin CM, Govindan R, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 2011; 6:1757-60; PMID:21918390; https://doi.org/10.1097/JTO.0b013e31822e2941
   PubMed Web of Science ®Google Scholar
• Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L. Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 2010; 31:984-93; PMID:20142415; https://doi.org/10.1093/carcin/bgq026
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, Shangary S, Qiu S, Gao W, Yang D, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49:6139-42; PMID:17034116; https://doi.org/10.1021/jm060460o
   PubMed Web of Science ®Google Scholar
• Zeitlin BD, Spalding AC, Campos MS, Ashimori N, Dong Z, Wang S, Lawrence TS, Nor JE. Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. Int J Radiat Oncol Biol Phys 2010; 78:879-87; PMID:20675079; https://doi.org/10.1016/j.ijrobp.2010.04.024
   PubMed Web of Science ®Google Scholar
• Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, Nor JE. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006; 66:8698-706; PMID:16951185; https://doi.org/10.1158/0008-5472.CAN-05-3691
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6:1-6; PMID:15068665
   PubMed Web of Science ®Google Scholar
• Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, Cheng YJ, Westra WH, Chen CJ, Hildesheim A, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res 2006; 66:7999-8006; PMID:16912175; https://doi.org/10.1158/0008-5472.CAN-05-4399
   PubMed Web of Science ®Google Scholar